SummaryRMgm-4385
|
Successful modification | The parasite was generated by the genetic modification |
The mutant contains the following genetic modification(s) | Gene disruption |
Reference (PubMed-PMID number) |
Reference 1 (PMID number) : 29233900 |
MR4 number | |
top of page | |
Parent parasite used to introduce the genetic modification | |
Rodent Malaria Parasite | P. yoelii |
Parent strain/line | P. y. yoelii 17XNL |
Name parent line/clone | Not applicable |
Other information parent line | |
top of page | |
The mutant parasite was generated by | |
Name PI/Researcher | Zhang C; Yuan J |
Name Group/Department | State Key Laboratory of Cellular Stress Biology, Innovation Center for Cell Signaling Network, Schoo |
Name Institute | Xiamen University |
City | Xiamen, Fujian |
Country | China |
top of page | |
Name of the mutant parasite | |
RMgm number | RMgm-4385 |
Principal name | ΔPyap2-g3 |
Alternative name | |
Standardized name | |
Is the mutant parasite cloned after genetic modification | Yes |
top of page | |
Phenotype | |
Asexual blood stage | Not different from wild type |
Gametocyte/Gamete | reduced numbers of male and female gametocytes |
Fertilization and ookinete | Not tested |
Oocyst | reduced numbers of male and female gametocytes; reduced numbers of oocysts |
Sporozoite | reduced numbers of male and female gametocytes; reduced numbers of oocysts; reduced numbers of sporozoites |
Liver stage | Not tested |
Additional remarks phenotype | Mutant/mutation (In P. berghei unsuccessful attempts to disrupt this gene has been reported) Other mutants |
top of page | |||||||||||||||||||||||||
Details of the target gene | |||||||||||||||||||||||||
Gene Model of Rodent Parasite | PY17X_1417400 | ||||||||||||||||||||||||
Gene Model P. falciparum ortholog | PF3D7_1317200 | ||||||||||||||||||||||||
Gene product | AP2 domain transcription factor, putative | ||||||||||||||||||||||||
Gene product: Alternative name | ApiAP2; AP2-G3 | ||||||||||||||||||||||||
top of page | |||||||||||||||||||||||||
Details of the genetic modification | |||||||||||||||||||||||||
Inducable system used | No | ||||||||||||||||||||||||
Additional remarks inducable system | |||||||||||||||||||||||||
Type of plasmid/construct used | CRISPR/Cas9 construct: integration through double strand break repair | ||||||||||||||||||||||||
PlasmoGEM (Sanger) construct/vector used | No | ||||||||||||||||||||||||
Modified PlasmoGEM construct/vector used | No | ||||||||||||||||||||||||
Plasmid/construct map | |||||||||||||||||||||||||
Plasmid/construct sequence | |||||||||||||||||||||||||
Restriction sites to linearize plasmid | |||||||||||||||||||||||||
Partial or complete disruption of the gene | Partial | ||||||||||||||||||||||||
Additional remarks partial/complete disruption | |||||||||||||||||||||||||
Selectable marker used to select the mutant parasite | hdhfr | ||||||||||||||||||||||||
Promoter of the selectable marker | eef1a | ||||||||||||||||||||||||
Selection (positive) procedure | pyrimethamine | ||||||||||||||||||||||||
Selection (negative) procedure | No | ||||||||||||||||||||||||
Additional remarks genetic modification | The gene has been disrupted using CRISPR/cas9 genome editing (using constructs as described for mutant RMgm-1095). To construct the vectors to disrupt the PyApiAP2 genes, we first amplified the 5'- and 3'-flanking genomic regions (400 to 700 bp) as left and right homologous arms. The left and right arms were inserted into the restriction sites (HindIII/KpnI and NcoI for the left arm and XhoI and AflII/EcoRI for the right arm) in the pYC plasmid (RMgm-1095). Sequences for single guide RNAs (sgRNAs) were similarly annealed and ligated into the pYC plasmid. | ||||||||||||||||||||||||
Additional remarks selection procedure | |||||||||||||||||||||||||
Primer information: Primers used for amplification of the target sequences
Primer information: Primers used for amplification of the target sequences
| |||||||||||||||||||||||||
top of page |